SPC25

Across TCGA pan-cancer cohorts, SPC25 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SPC25 data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SPC25 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated SPC25 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

PDAC, HNSC, and LSCC are the cancer types where SPC25 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	All	0.198	0.554	.004	51	view →
HNSC	OS	Quartile	All	0.167	0.966	.010	27	view →
LSCC	DFS	Tertile	All	0.834	0.607	.019	9	view →
LUAD	OS	Quartile	II,III,IV	0.228	0.841	.033	3	view →
UCEC	DFS	Median	All	0.801	0.932	.030	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SPC25–PDAC (OS)

Open the PDAC breakdown →